The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions
- 1 February 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Nuclear Medicine Communications
- Vol. 32 (2), 106-112
- https://doi.org/10.1097/mnm.0b013e32834199e7
Abstract
Objectives This retrospective study was designed to investigate the clinical role of whole-body positron emission tomography/computed tomography (PET/CT) by using 2-[18F]fluoro-2-deoxy-D-glucose (FDG), for the evaluation of adrenal lesions and to find the best index to distinguish benign from malignant lesions in various cancer patients. Materials and methods A total of 81 patients (55 male and 26 female, age range: 31–81 years, mean: 61.5) who had confirmed primary malignancies (lung cancer in 47 patients, gastrointestinal malignancies in 13 patients, malignant melanoma in one patient, renal cell cancer in three patients, mesothelioma in two patients, breast carcinoma in nine patients, cervical cancer in one patient, ovarian cancer in two patients, pheochromocytoma in one patient, unknown primary in two patients) underwent PET/CT examinations for cancer screening, staging, restaging, and detection of suspected recurrence. Of the 81 patients, 104 adrenal lesions (34 benign and 70 malignant adrenal lesions) were shown by CT. On visual analysis of PET/CT imaging, adrenal uptake was based on a three-scale grading system. For final assessment standards of references for adrenal malignant lesions was based on biopsy (n=2), interval growth, or reduction after chemotherapy. An adrenal lesion, which remained unchanged on clinical and imaging follow-up of at least 7 months (mean follow-up time 19.31 months±6.46, range 7–30 months), was decided as a benign lesion. Results In adrenal malignant lesions maximum standardized uptake value (SUVmax) (8.82±4.47) was higher than that of adrenal benign lesions (3.02±1.15, Pmax cut-off value of 2.5 corresponded to a sensitivity of 100%, specificity of 38.2%, and accuracy of 80%. An SUVmax cut-off value of 4.2 corresponded to a sensitivity of 88.6%, specificity of 88.2%, and accuracy of 88.5%. The ratio of tumor SUVmax to liver SUVmean was 3.61±1.77 for adrenal malignant lesions whereas it was 1.20±0.38 for adrenal benign lesions (P18F]fluoro-2-deoxy-D-glucose-PET/CT improves the diagnostic accuracy in the differentiation of benign from malignant adrenal lesions in various cancer patients. Combined information obtained from PET/CT (SUVmax, T/L SUV ratio, visual analysis) and unenhanced CT (size, Hounsfield units measurement) is recommended for better differentiation.Keywords
This publication has 20 references indexed in Scilit:
- Utility of Diffusion-Weighted MRI in Characterization of Adrenal LesionsAmerican Journal of Roentgenology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Utility of PET/CT in Differentiating Benign from Malignant Adrenal Nodules in Patients with CancerAmerican Journal of Roentgenology, 2008
- Differentiating Adrenal Adenomas From Nonadenomas Using 18F-FDG PET/CT: Quantitative and Qualitative EvaluationAcademic Radiology, 2007
- Changing Role of Imaging-Guided Percutaneous Biopsy of Adrenal Masses:Evaluation of 50 Adrenal BiopsiesAmerican Journal of Roentgenology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions.American Journal of Roentgenology, 1999
- Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature.American Journal of Roentgenology, 1998
- Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.American Journal of Roentgenology, 1997
- CT-guided adrenal biopsy: accuracy, safety, and indicationsAmerican Journal of Roentgenology, 1985